Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21290883 | 1.00 | ATM (0.53) | ATMCD274PDCD1MMERIPK1 | |
| SCHEMBL5067978 | 1.00 | ATM (0.53) | ATMCD274PDCD1MMERIPK1 | |
| SCHEMBL12155273 | 0.85 | ATM (0.50) | ATMCD274PDCD1GAA | |
| SCHEMBL8894208 | 0.85 | ATM (0.50) | ATMCD274PDCD1GAA | |
| SCHEMBL14355763 | 0.85 | ATM (0.50) | ATMCD274PDCD1GAA | |
| SCHEMBL12191622 | 0.85 | ATM (0.50) | ATMCD274PDCD1GAA | |
| SCHEMBL26999793 | 0.84 | ATM (0.40) | ATMCD274GAA | |
| SCHEMBL21618694 | 0.84 | ATM (0.40) | ATMCD274GAA | |
| SCHEMBL20158970 | 0.82 | MAOA (0.40) | ATMGAA | |
| SCHEMBL9965183 | 0.82 | ATM (0.39) | ATMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5665371-A | SIDE EFFECT REDUCTION | HOERRMANN WILHELM (DE) | 1997-09-09 | — | — | US | claimed |
| US-20180201838-A1 | FLAME-RETARDANT POLYOLEFIN SYSTEMS | BASF SE (DE) | 2018-07-19 | — | — | US | disclosed |
| US-8871778-B2 | Substituted pyrimidine compounds and their use as SYK inhibitors | GENOSCO (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130274242-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS SYK INHIBITORS | Genosco Inc. | 2013-10-17 | — | — | US | disclosed |
| WO-2013109882-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS SYK INHIBITORS | GENOSCO (US) | 2013-07-25 | — | — | WO | disclosed |
| US-8389508-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-20120077711-A1 | Novel Ligands and Libraries of Ligands | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-20110269738-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| WO-2010100142-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | MERCK SERONO S.A. (CH) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269738-A1 | COMPOUNDS | CYP11B2, CYP11B1, GPR119 | ATM 4555/4885CD274 4827/4885PDCD1 4739/4885 |
| US-20130274242-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS SYK INHIBITORS | SYK, BTK, LCK | ATM 220/4885CD274 2033/4885PDCD1 1547/4885 |
| US-20120077711-A1 | Novel Ligands and Libraries of Ligands | LSS, ABCG2, SELL | ATM 4042/4885CD274 707/4885PDCD1 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.